Startup Scout 12 Oct 2018 This Biotech is the First to Work on Antivirals for Farm Livestock While in Leuven, Belgium, for last week’s Biotech of the Week, we decided to go to the vet. ViroVet is a company aiming to improve viral disease control in livestock, which is a huge sector of global agriculture. Mission: To develop novel antivirals and vaccines for farm livestock. This would give farmers more tools for […] October 12, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2018 Update: Series A Boost Pushes Belgian Microbiome Spin-Off Forward Update (27/09/2018): New investment from Dutch venture capital fund Innovation Industries brings A-Mansia’s Series A round up to €18M. The company’s first human study of the effects of A. muciniphila in volunteers is currently underway at the University of Louvain. Published on 27/04/2018 A-Mansia Biotech has raised €13M in Series A financing led by Seventure Partners. The […] September 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2018 Cell Therapy Helps Regenerate Difficult Bone Fractures All patients in a clinical trial run by the Belgian company Bone Therapeutics have seen an improvement in the healing of bone fractures that have had problems healing. Six months after receiving a single dose of the cell therapy developed by Bone Therapeutics, all 21 patients in the Phase I/IIa clinical trial met the primary […] September 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2018 The EMA Approves the First Nanobody from Ablynx Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in June. The drug has also been accepted for priority review by the US FDA, with a decision due on 6 Feb 2019. Published 29.6.18 Just a few months after Sanofi acquired Ablynx in a multi-billion euro […] September 4, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2018 Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world’s leading causes of vision loss. Results from the Phase I/II trial demonstrate the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against […] July 20, 2018 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2018 A New HIV Vaccine Could Protect Patients Against Multiple Viral Strains A new HIV vaccine is moving into a Phase IIb trial and could potentially protect patients against multiple HIV strains worldwide. Recent findings from a Phase I/IIa trial published in The Lancet show that a new HIV-1 vaccine was safe and produced an immune response against HIV 393 healthy adults, as well as in a […] July 6, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2018 Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […] June 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 17 May 2018 The First In-Human Trial of an Eye Implant Helps Patients With Glaucoma iSTAR Medical has obtained promising results from the first-in-human trial of an eye implant, that can decrease fluid pressure in the eyes of glaucoma patients. iSTAR Medical, a Belgian biotech, has six-month results from a first-in-human trial showing the effects of its device on intraocular pressure in patients with glaucoma — a condition where high eye […] May 17, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“ Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […] April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2018 Cheese-Producing Bacteria Could Help Reverse Type 1 Diabetes ActoBio Therapeutics has received permission from the FDA to start a clinical trial for a type 1 diabetes treatment that uses a bacterial strain also used in cheese production. After being cleared by the FDA, ActoBio, based in Belgium, plans to begin a PhaseIb/IIa study for its drug, AG019, to treat early-onset type 1 diabetes. What makes […] April 3, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2018 Belgian Firm Raises €19M to Fix Spinal Fusion with Cell Therapy Bone Therapeutics has raised €19.5M through a private placement that will fund the completion of clinical trials testing its cell therapy for spinal fusion and other bone diseases. Based in Groselies, Belgium, Bone Therapeutics wants to use cell therapy to help people with bone injuries or diseases regenerate healthy bone. In order to complete its […] March 8, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M in January, ASIT Biotech has now brought the amount raised on the Euronext Brussels stock up to €13.9M. The funds will be put towards the Phase III […] February 26, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email